ampelopsin has been researched along with Ventricular Dysfunction, Left in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, H; Lin, H; Lin, N; Lu, W; Meng, L; Ni, T; Sun, Z; Zhang, C; Zhang, J | 1 |
1 other study(ies) available for ampelopsin and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Dihydromyricetin alleviates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome through activation of SIRT1.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Cardiotoxicity; Cell Line; Cell Survival; Doxorubicin; Flavonols; Heart; Inflammasomes; Male; Myocardium; Myocytes, Cardiac; NLR Family, Pyrin Domain-Containing 3 Protein; Rats; Rats, Sprague-Dawley; Sirtuin 1; Ventricular Dysfunction, Left | 2020 |